Form 4: Ionis Pharma Exec's Stock Transactions & Equity Grants

Ionis Pharmaceuticals EVP Kyle Jenne reported recent stock transactions, including RSU vesting, a tax-related stock sale, and new equity grants.

Summary

• Kyle Jenne, EVP, Chief Global Product Strategy Officer at Ionis Pharmaceuticals Inc. (IONS), reported several transactions involving company stock and derivative securities.
• On January 15, 2026, 7,013 shares of common stock were acquired due to the vesting and release of Restricted Stock Unit (RSU) awards.
• Following this acquisition, Jenne beneficially owned 18,212 shares of common stock.
• On January 16, 2026, 1,823 shares of common stock were sold at a weighted average price of $75.96 per share to cover tax withholding obligations related to the RSU vesting.
• After the sale, Jenne's direct beneficial ownership of common stock decreased to 16,389 shares.
• On January 15, 2026, Jenne was granted 25,800 Performance Restricted Stock Units (PRSUs) under the 2011 Equity Incentive Plan, representing the maximum number that may be earned.
• Also on January 15, 2026, Jenne was granted 9,675 Restricted Stock Units (RSUs) under the same plan.
• The filing indicates a beneficial ownership of 44,500 PRSUs and 37,725 RSUs following these grants, with 7,013 RSUs disposed due to vesting, resulting in 29,664 RSUs beneficially owned after that specific vesting event.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive due to the new grants of Performance Restricted Stock Units and Restricted Stock Units, which align executive incentives with company performance and retention. The stock sale for tax purposes is a neutral, routine event.

Positives

• The grant of 25,800 Performance Restricted Stock Units (PRSUs) aligns executive incentives with long-term shareholder returns.
• The grant of 9,675 Restricted Stock Units (RSUs) represents ongoing equity compensation and retention for a key executive.

Negatives

• The sale of 1,823 shares of common stock, although for tax withholding, reduces the executive's direct ownership in the company.

Risks

• The Performance Restricted Stock Units (PRSUs) may vest at the end of a three-year performance period based on the Issuer's relative total shareholder return compared to a peer group, meaning the actual number of PRSUs that will vest may range from zero to the maximum stated amount (25,800 units).

Future Outlook

The Performance Restricted Stock Units (PRSUs) are designed to vest at the end of a three-year performance period, contingent on the Issuer's relative total shareholder return compared to a peer group, aligning future executive compensation with company performance.

Management Comments

• The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.
• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the reported range upon request.

Industry Context

This Form 4 filing details routine executive compensation activities, including equity grants and tax-related stock sales, which are common practices across publicly traded companies, particularly in the biotechnology and pharmaceutical sectors, to incentivize and retain key management.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of performance-based equity awards (PRSUs) aims to align executive interests with long-term shareholder value creation. The transparency of these transactions provides insight into executive compensation.
• Employees: The equity incentive plan provides a framework for executive compensation, which can influence broader compensation strategies within the company.

Next Steps

• The Performance Restricted Stock Units (PRSUs) will be subject to a three-year performance period, with vesting determined by the company's relative total shareholder return against a peer group.
• The newly granted Restricted Stock Units (RSUs) will vest in four equal annual installments.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Form 4, Insider Transaction, Executive Compensation, Restricted Stock Units, Performance Restricted Stock Units, Equity Incentive Plan, Stock Sale, Vesting